Twenty-one patients with metastatic colorectal adenocarcinoma, all previously treated with chemotherapy for metastatic disease, were treated with lonidamine (LDN). The major toxicity encountered was muscular (myalgias in 48%) and gastrointestinal (nausea and/or vomiting in 52%). Other toxicities included abdominal pain, somnolence, fever, arthralgia and ototoxicity. In the 14 patients evaluable for response we observed no complete or partial remission, 8 stable disease and 6 progressive disease. LND has no clinically worthwhile activity against colorectal carcinoma refractory to conventional chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
BandP., MarounJ., PritchardK., CoppinC., WilsonK., EisenhauerE.: Phase II study of lonidamine (LDM) in advanced breast cancer.Proc. Am. Soc. Clin. Oncol., 5: 216, 1986.
2.
BandP.R., DeschampsM., BesnerI.G., LeclaireR., GervaisP., De SanctisA.: Phase I toxicology study of lonidamine in cancer patients.Oncology (Basel), 41(Suppl. 1): 56–59, 1984.
3.
BattelliT., ManocchiP., MattioliR., GinnettiA., De GregorioM., De MartinoC., SilvestriniB.: A long-term clinical experience with lonidamine.Oncology (Basel), 41(Suppl. 1): 39–47, 1984.
4.
CaputoA., SilvestriniB.: Lonidamine, a new approach to cancer therapy.Oncology (Basel), 41(Suppl. 1): 2–6, 1984.
5.
CorsiG., PalazzoG., GermaniC., Scorza BarcellonaP., SilvestriniB.: 1-Halobenzyl-1H indazole-3-carboxylic acids. A new class of antispermatogenic agents.J. Med. Chem., 19: 778–783, 1976.
6.
EvansW.K., ShepherdF.A., MullisE.: Phase II evaluation of lonidamine in patients with advanced malignancy.Oncology (Basel), 41(Suppl. 1): 56–77, 1984.
7.
FloridiA., PaggiM.G., D'AltriS., De MartinoC., MarcanteM.L., SilvestriniB., CaputoA.: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.Cancer Res., 41: 4661–4666, 1981.
8.
FloridiA., PaggiM.G., MarcanteM.L., SilvestriniB., CaputoA., De MartinoC.: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.J. Natl. Cancer Inst., 66: 497–499, 1981.
9.
KemenyN., GolbeyR.: A chemotherapeutic approach to colorectal carcinoma. In: Neoplasm of the Colon, Rectum and Anus.StearnsM.W.Jr. (ed.), pp. 155–168, John Wiley and Sons, New York, 1980.
10.
KimJ.H., AlfieriA.A., KimS.H., YoungC.W.: Potentiation of radiation effects on two murine tumors by lonidamine.Cancer Res., 46: 1120–1123, March 1986.
11.
KimJ.H., AlfieriA.A., KimS.H., YoungC.W., SilvestriniB.: Radiosensitization of Meth-A-fibrosarcoma in mice by lonidamine.Oncology (Basel), 41(Suppl. 1): 36–38, 1984.
12.
MurrayN., BandP., ShahA.: Phase II study of lonidamine in small cell lung cancer.Proc. Am. Soc. Clin. Oncol., 5: 680, 1986.
13.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
14.
PetrelliN., HerreraL., RustumY., BurkeP., CreavenP., StulcY., EmrichJ.L., MittelmanA.: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.J. Clin. Oncol., 5: 1559–1565, 1987.
15.
SilvestriniB., HahnG.M., CioloV., De MartinoC.: Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.Br. J. Cancer, 47: 221–231, 1983.
16.
YoungC.W., CurrieV.E., KimJ.H., O'HehirM.A., FaragF.M., KinahanJ.E.: Phase I and clinical pharmacological evaluation of lonidamine in patients with advanced cancer.Oncology (Basel), 41(Suppl. 1): 60–65, 1984.
